Related Articles
FDA questions data on MDMA-based therapy in PTSD ahead of advisory committee
The FDA questioned data around Lykos Therapeutics’ MDMA-based therapy for post-traumatic stress disorder on Friday, less than a week before its advisory committee meets to…
FDA approves Moderna’s RSV vaccine, marking its second approved product
Moderna on Friday secured a long-awaited but expected approval for its RSV vaccine, giving the biotech its first FDA approval for a non-Covid-19 product and…
FDA approves Moderna’s RSV vaccine, marking its second approved product
Moderna on Friday secured a long-awaited but expected approval for its RSV vaccine, giving the biotech its first FDA approval for a non-Covid-19 product and…
Doctors who endorse drugs on social media are often compensated, JAMA study finds
Physicians who posted endorsements of drugs on social media often received cash payments from industry, and in some cases didn’t disclose that they had been…
Doctors who endorse drugs on social media are often compensated, JAMA study finds
Physicians who posted endorsements of drugs on social media often received cash payments from industry, and in some cases didn’t disclose that they had been…
Flush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1 profits into regenerative medicines
The Novo Nordisk Foundation, the majority owner of Novo Nordisk, plans to put more money into regenerative medicines, including stem cells and cell therapies for…
Startup launches with ‘RNA sensor’ technology from Stanford and MIT to better control mRNA therapies
Finding a way to deliver genetic medicines to the right parts of the body is one of the most technologically vexing problems in the biotech…
Merck returns to lucrative eye disease market in up to $3B deal for EyeBio
A decade after departing the ophthalmology drug market, Merck is launching a return to the field in a $1.3 billion upfront cash acquisition for Series…
After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray
James Sabry, the longtime doyen of biotech dealmakers from his global perch at Roche/Genentech, is jumping to the US biotech scene. The Basel-based pharma giant…
Novo reports ‘really powerful’ cardio, death risk reduction for semaglutide in kidney disease
Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2…